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Abstract: Subarachnoid hemorrhage (SAH) is a life-threatening stroke caused by bleeding in the
subarachnoid space. Delayed cerebral ischemia, a risk factor for death during non-traumatic SAH
treatment, is often prevented by inducing hemodynamic augmentation through the administration
of vasopressors. The three common vasopressors administrated to SAH patients are dopamine,
phenylephrine, and norepinephrine. A recent study using Electronic Health Records (EHR) of nontraumatic SAH patients identified that the administration of phenylephrine is associated with lower
hospital mortality; however, this study did not consider heterogeneity in treatment effects.
Therefore, the goal of this paper is to study the heterogeneity in vasopressor treatment effects by
exploratory subgroup analyses. The subgroups were identified by studying the vasopressor and
pretreatment covariates interaction effects. We employed a machine learning and a generalized
linear model approach to study the interaction effects. We also employed propensity scoring and

inverse probability weighting to minimize the confounding and selection biases in treatment effect
estimates due to inherent pretreatment group differences in the data. Our results showed that
dopamine had the highest mortality among those who did not have ondansetron ( a pretreatment
medication used to prevent nausea) compared to phenylephrine and norepinephrine; whereas
norepinephrine has the highest mortality among those who had ondansetron compared to
phenylephrine and dopamine. However, for the subgroup who did not have ondansetron but had
fentanyl and lidocaine, there was no significant difference in the mortality rate between
vasopressor treatment group. Overall, those who had ondansetron had better survival compared to
those who did not have ondansetron with respect to all the three vasopressors.
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Study Background
Stroke and SAH
Stroke is the fifth leading cause of death in 2016, and it accounts for 1 in 20 deaths across
the United States (U. S.). 4 Two main types of stroke are ischemic stroke and hemorrhagic stroke.
Ischemic stroke is a common stroke caused by a blood clot that blocks a blood vessel in the brain.
It accounts for 80% of all cases and it transpires because of oxygen deprivation in the brain. In
comparison, a hemorrhagic stroke occurs when a

blood vessels ruptures, and bleeds into the

intracerebral space (referred to as intracerebral hemorrhage, ICH) or subarachnoid space (referred
to as subarachnoid hemorrhage, SAH). SAH constitutes 5-10% of strokes annually reported in the
U. S.1 SAH can occur due to trauma or non-trauma conditions, differing in their underlying
pathophysiology. Among the non-trauma SAH cases, 85% is due to a ruptured aneurysm, while
the remaining 15% are due to nonaneurysmal perimesencephalic bleeding and other causes.3 The
estimated incidence of nontraumatic SAH in the U. S. during 1979-2008 was 7.2 to 9.0 per 100,000
per year.2 Metanalysis of 51 studies through October 2005 showed a worldwide incidence of
nontraumatic SAH of approximately 9 per 100,000 person-years.5
A retrospective cohort study of non-traumatic SAH patients reported an in-hospital
mortality rate of 14%.2 Concurrently during SAH, patients can also experience delayed cerebral
ischemia (DCI), one of the primary causes of in-hospital mortality. DCI is linked to cerebral
vasospasm, a vascular constriction of cerebral vessels after SAH. Usually, between 20-40% of the
SAH patients would develop cerebral vasospasm.6 Among those affected, 50% will die or suffer
permanent neurological damage.6 However, DCI in patients presenting with SAH could often be
prevented by inducing hemodynamic augmentation to maintain cerebral perfusion. Administration
1

of vasopressors is a widely held medical practice for inducing hypertension.7,8 Three common
vasopressors administered are dopamine, phenylephrine, and norepinephrine, but which of these
vasopressors should be chosen as the first-choice treatment still remains unknown.
Currently, no prospective comparative study on vasopressor treatment choice for SAH patient are
available. However, it is believed that vasopressor choice is patient specific, and it depends on the
one’s prior diagnosis and medication.9 A recent retrospective study, I have been a part of, using
the Cerner Health Facts Electronic Health Records (EHR) data (n=2535) found that phenylephrine
is associated with lower hospital mortality (under review). However, we cannot generalize this
observation to all subjects because each subject may have a different treatment response.
Therefore, the goal of this paper is to study the differential effect of vasopressor by exploratory
subgroup analyses.

Electronic Health Record (EHR), Cerner Health Facts
EHR is a longitudinal electronic record of patient health information generated by one or more
encounters in any healthcare delivery setting.14 Although EHR has been primarily used for
structured billing and records, with advances in big data analysis and machine learning
methodologies, it is now being utilized for quantitative analysis to improve patient care and to
identify optimal treatments or treatment strategies, including outcomes research and
epidemiological studies. A major provider for the EHR systems in the U. S. is the Cerner
Corporation in North Kansas City, Missouri.15 In this study, we used the SAH patient records from
the Cerner health facts database hosted by SBMI (School of Biomedical Informatics) at UT Health
Science Center. This is a publicly available relational database comprising of multicenter de-
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identified 106 million health records. The data contain patient records across 700 participating
Cerner client hospitals and clinics from 2000 to 2015 in the U. S.
EHR includes individual patient records on demographics, diagnosis history, medication history,
clinical procedure, vital signs, lab records, and billing information. Each patient record follows the
key standards for clinical vocabularies, such as Current Procedure Terminology (CPT) codes for
clinical procedures, International Classification of Diseases (ICD) for diagnoses and Logical
Observation Identifiers, Names and Codes (LOINC) for ordering lab tests. Since these standards
are implemented uniformly across medical institutions, patient data from different institutions can
be combined to make nationally representative data. Aggregated EHR data such as Cerner health
facts then give access to a large amount of data that are useful for studying rare events such as
SAH. EHR data also have a large number of variables that can be studied simultaneously. For
issues such as missing data and data quality16,17 in the EHR data and the presence of correlated
covarites, an appropriate staitical method such lasso modeling and propensity scring were
employed in our analysis.

Specific Aims
The objective of this thesis is to identify patient subgroups for which vasopressor has
differential treatment outcomes. Identifying these patient subgroups would help to inform the
optimum vasopressor choice among dopamine, phenylephrine, and norepinephrine from a patientspecific perspective. The differential effect of vasopressor treatment for SAH patients was studied
by exploratory subgroup analyses in this paper. To conduct subgroup analyses, we utilized two
approaches: a generalized linear model and a machine learning approach. In the generalized linear
model approach, we employed lasso regression for feature selection; and applied propensity
scoring to reduce the effects of observed confounding and to obtain unbiased estimates of the
3

average treatment effects. False Discovery Rate (FDR) approach22 was then used to correct for
multiple comparisons. We also employed a machine learning method, a recursive partitioning
method for classification and regression. The theory behind lasso, propensity scoring, and
recursive partitioning method are discussed in the Methods section.
The specific aims are as follows:
1. Conducting a statistical, retrospective exploratory subgroup analysis of vasopressor
treatment effects in SAH patients on mortality outcome via a generalized linear model
(GLM) approach:
a. Constructing covariate balanced data using propensity score modeling and inverse
probability treatment weighting.
b. Identifying demographic, medication, and vital sign variables associated with
patient mortality.
c. Identifying significant interactions between different vasopressor treatments and
covariates, adjusting for variables selected in 1b. Interaction p-values were adjusted
for multiple testing.
d. Studying the magnitude of treatment effect among the subgroups identified through
significant interaction effects.
2. Conducting a machine learning, data-driven tree-based recursive partitioning approach
to explore heterogeneity in vasopressor treatment effects.
3. Comparing the subgroups from (1) GLM and (2) machine learning approaches
We hypothesize that there is an interaction effect of pretreatment covariates on the
relationship between vasopressor treatment effect and mortality. Any identified interaction effect
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will show the presence of subgroups within the SAH patients. This could then generate potential
new hypotheses for future studies of personalized medicine in SAH patients receiving vasopressor
treatments.

Public Health Significance
SAH patients have a high mortality rate. Currently, patients are mainly treated using three
vasopressors: dopamine, phenylephrine, and norepinephrine. In the absence of clinical trials on
vasopressor choice, the decision has often to be made by physicians based on their experience and
the patient’s hemodynamic status, comorbid conditions, and institutional preferences, which may
affect patient outcomes after the diagnosis of SAH. The data-driven subgroup analysis using the
EHR data in this study can then highlight the differences in different patients’ responses to
vasopressor treatment. Results from our analysis can be used as hypothesis generating for the
guideline in designing future clinical trials; and choosing the optimal vasopressor for a group of
SAH patients. In the long term, our study also has the potential to improve SAH treatment and
reduce the mortality rate among SAH paitents.

Method
Subgroup analysis is a topic of great interest specifically with an eye towards more
personalized medicine. It is useful in determining the heterogeneity of treatment effects, and it is
critical to identify the positive and negative effects of the treatment. Subgroup analyses can be
conducted either as pre-specified or during post-hoc reviews. In a pre-specified subgroup analysis,
hypotheses about which subgroups to examine are predefined. In clinical trials, subgroups are often
defined at the design stage based on prior insights or the exploratory analyses of other datasets. In
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this thesis, we will conduct an exploratory analysis for subgroup identification by examining all
possible subgroups.
However, there exist several limitations and pitfalls of post-hoc subgroup analyses. A
major limitation of a subgroup analysis is its risk of increasing the probability of finding
statistically significant findings due to chance. Due to multiple tests, a study can run into a risk of
false positives during the post hoc analysis. Nevertheless, multiplicity correction using FDR can
reduce this effect. Moreover, if we test the statistical interaction between treatment and some
subgroups first, and then test within the subgroups only if a certain interaction is significant, we
could reduce the number of tests conducted. So, in this thesis, we used both multiplicity correction
and limited number of tests to avoid false positive during the post hoc analysis.
Subgroup analysis can also lead to false negatives due to inadequate power. Brookes ST et
al10, used a simulation study to quantify the power of interaction test in trials designed to detect
the overall treatment effects. They looked at different scenarios of the overall treatment and
subgroup effects using both continuous and binary outcomes, and they found that if a trial has 80%
power for the overall effect, the power to detect the interaction effect of the same magnitude is
only 29%. They also pointed out that to detect the interaction effect of the same magnitude with
the same power as the overall effect, the sample size needs to be fourfold.10 However, even with
these limitations, subgroup analyses are still often conducted to extract information from data for
hypothesis generation. Of course, one has to follow several guidelines while reporting and
interpreting the results.11,12,13 Therfore, in this thesis, to identify subgroups, we evaluated multiple
covariate interaction effects on vasopressor treatment choices for a SAH patient outcome model.
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When constructing the SAH patient outcome model to account for confounding, it would
be appropriate to incorporate as many variables as available. However, there is a risk of overfitting
the model, resulting in a numerically unstable estimate. Overfitting could also reduce the power
of prediction for future data due to the presence of noise18,19 and violation of the principle of
parsimony. A parsimonious model should include no more predictors than necessary. Peduzzi et
al20 proposed a guideline regarding the number of predictors that should be included in statistical
models. This guideline suggests including at least 10 outcomes of each type for every independent
variable to avoid over-estimated and under-estimated variance. Hosmer and Lemeshow21
suggested the number of parameters (𝑝 + 1) in a logistic regression model should be ≤
min(𝑛0 , 𝑛1 ) /10, where, 𝑛1 is the number of events of type 1, and 𝑛0 is the number of events of
type 2 of a binary dependent variable. In the SAH data, 𝑛1 = 1895 and 𝑛0 = 2720; hence, by above
mentioned criteria, we could include a maximum of 189 parameters. Hence it is important to
choose an appropriate statistical method to find important predictors to fit a parsimonious model.
Another important issue that needs to be addressed is confounding. Confounding occurs if the
SAH patients who received one vasopressor differed systematically from those receiving a
different vasopressor in terms of pretreatment covariates. However, this could be addressed by
removing or minimizing the effect of confounding through choosing a suitable statistical method
such as propensity scoring.

Overview of the proposed analysis

Generalized linear models and machine learning approaches are used to identify the significant
interaction effect between vasopressor and pretreatment covariates within the SAH patient data.
The generalized linear model analysis included four steps. First, the propensity score, which is
7

defined as the probability of receiving a treatment conditional on observed pretreatment covariates.
It was calculated using Generalized Boosted Models (GBM), a flexible estimation method that can
adjust for many pretreatment covariates.23 Prior to GBM, we used the L1-penalized multinomial
logistic regression (GLM Multinomial Lasso) to identify important factors associated with
vasopressor treatment. These selected variables were used as input variables in GBM to obtain the
propensity score. Obtained scores were then used as weights in the mortality outcome model whicn
test for interactions in the third step. The second step involved using L1-penalized logistic models
(GLM Logistic Lasso) to select the important factors associated with mortality. The selected
variables were then used as the main effects for the outcome model in the third step. In the third
step, a base outcome model was constructed using weights from the first step, the main effects
from the second step and the vasopressor treatment variable. Further, an interaction model was
also constructed with the treatment interaction with each main effect covariate identified from the
second step. Finally, the base model and interaction model were compared using the Likelihood
ratio test (LRT). In order to account for the multiplicity correction in LRT, the FDR adjusted pvalue was used to identify significant interaction effects. Any significant interactions identified
would highlight the difference in the effect of vasopressor on mortality conditional on the presence
or absence of that main effect. Further, we conducted Model-based Recursive Partitioning (MOB),
a machine learning approach for subgroup analysis. We then compared the generalized linear
model result with the MOB result.

Data Summary
In this study, we used the SAH patient records queried from the Cerner Health Facts® database.
This database is hosted by SBMI, UT Health Science Center and accessed through an appropriate
IRB approval (IRB HSC-MS-18-0124). Our data included de-identified patient-level electronic
8

health records from 700 hospitals and clinics that use Cerner Corporation’s EHR system. These
correspond to 39,017 patients with at least one SAH encounter.
Inclusion/Exclusion criteria: From the 39,017 SAH patient records, our study population was
identified based on the following criteria: (1) Only records with diagnosis history on ICD-9 code
(430,800.2x, 800.7x, 801.2x, 801.7x, 803.2x, 803.7x, 804.2x, 804.7x, 852.x) with medication
history of at least one of the vasopressor medications norepinephrine, phenylephrine or dopamine
were included (N=4,850). (2) SAH patients below the age of 17 were excluded. (3) SAH patients
who received multiple vasopressor treatments simultaneously as initial treatment were excluded
(n=40). (4) SAH patient who had a diagnosis of the traumatic cause of SAH were excluded
(n=2176).
Date cleaning: Observations with Mortality = “Unknown” (n=93), Gender = “Unknown” (n=2)
and those with missing medication information were all omitted from the analysis. Further,
pretreatment medication variables with less than 10 occurrences were also excluded.
Study population: The study population included non-traumatic SAH patients over the age of 17
with a single encounter or multiple encounters for SAH (N= 2415). When a patient had multiple
encounters separated by less than a day, the encounters were then combined into a single encounter
otherwise only data from the first encounter were used in the analysis. A subsample of size N=
940 included the data of baseline heart rate, baseline systolic and diastolic blood pressure, and all
these data were used for sensitivity analysis.
Exposure: The primary exposure of interest is the first vasopressor administered to eligible
patients, either phenylephrine, dopamine, or norepinephrine.
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Outcome: The outcome for this study is the mortality rate which is defined as death at hospital or
discharge to hospice. Mortality will be coded as 1 (death or discharge to hospice) and 0 (survived).
Our final cleaned data consisted of 2,415 patients’ records, and each was identified using an
individual identifier (variable Patient_SK). The data also included age in years, race (African
American=549, White= 1609, other = 257), marital status (divorced=258, married= 1098, single=
637, widowed=180, unknown= 242), gender (female=1536 , male=879), mortality, vital signs
(heart rate, systolic blood pressure and diastolic blood pressure) and total fluids administered
(sum_IVF). Appendix I shows a summary of all the variables. Additionally, in the Cerner database,
because we did not have timing information for diagnoses, we could not differentiate whether the
observed diagnoses were pretreatment or post-treatment factors. Hence, diagnosis factors were not
included in our analysis.

Statistical Analysis
The analysis was performed using R software (R Foundation for Statistical Computing, Vienna,
Austria). Specifically, we used ANOVA or Kruskal-Wallis test to compare the continuous
variables among the vasopressor treatment groups. For categorical factors, we used the Chi-square
test. The following subsection describes the various statistical methods used in our analysis.
Least absolute shrinkage and selection operator (Lasso)
L1-penalized regression (also referred to as Lasso) was used to select the important factors
associated with the dependent variable of interest. We applied Lasso prior to GBM and the
treatment-covariate interaction studies to identify the important factors associated with
vasopressor and mortality, respectively. Lasso is a regularization and feature selection method first
formulated by Robert Tibshirani in 1996. In high dimensional data such as EHR where the number
10

of features is larger than the number of observations, a sparse statistical model such as lasso would
be appropriate since it involves regularization techniques of penalizing the absolute size of the
regression coefficients. Lasso shrinks the less important feature’s coefficient to zero, thus
removing some less important features altogether. The purpose of the shrinkage is to prevent
overfit arising due to collinearity of the covariates or high-dimensionality. Lasso could minimize
𝑘

the sum of squared error subject to an 𝑙1 penalty term 𝜆 ∑ |𝛽𝑗 | , where λ ≥ 0 is a tuning parameter.
𝑗

When λ =0, the Lasso estimate is equivalent to the least squares estimate. When λ is sufficiently
large, coefficients are forced to be exactly equal to zero, which help us attain dimensionality
reduction.
Lasso estimator for GLM

The Generalized Linear Models (GLM) is a broad class of the linear regression models that allow
analysis of different types of univariate response. Standard linear regression is a special case of
GLM for the normally distributed continuous response; likewise, logistic regression is GLM for
binary response, and log-linear regression is GLM for counts data. GLM consists of three main
components:
1. Random component: GLM assumes that the probability distribution of the response variable is
from an exponential family distribution including normal, Bernoulli, binomial and Poisson
distributions. The random component defines a probability distribution for the response variable,
𝑌𝑖 . In a logistic regression model, the probability distribution of the response variable follows a
Binomial distribution.
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2. Systematic component: Systematic component specifies the effect of an explanatory variable on
the mean of Y, which can be expressed as a linear combination of these predictors:
𝜂 = 𝛽0 + 𝛽1 𝑋1 + 𝛽2 𝑋2 + … + 𝛽𝑘 𝑋𝑘
2. Link function: This component specifies a function g(.) that relates the expected value of Y, 𝜇
to the linear predictors. That is, a link function connects the systematic and random component as
𝑔(𝜇) = 𝛽0 + 𝛽1 𝑋1 + 𝛽2 𝑋2 + … + 𝛽𝑘 𝑋𝑘
For logistic regression, the link function is the logit function.
𝑔(𝜇) = 𝑙𝑜𝑔𝑖𝑡(𝜇) = log (

𝜇
) = 𝛽0 + 𝛽1 𝑋1 + 𝛽2 𝑋2 + … + 𝛽𝑘 𝑋𝑘
1−𝜇

For GLM, lasso estimator is defined by penalizing the negative log-likelihood with the 𝑙1-norm.
The negative log-likelihood is
− ∑𝑛𝑖=1 log(𝑝𝛽 (𝑌𝑖 |𝑋𝑖 ))

(1)

The equation (1) in terms of the loss function can be expressed as
𝑛−1 ∑𝑛𝑖=1 𝜌𝛽 (𝑋𝑖 , 𝑌𝑖 )

(2)

𝜌𝛽 (𝑥, 𝑦) = −log(𝑝𝛽 (𝑦|𝑥))

(3)

Then, the 𝑙1-norm penalized Lasso estimator is defined as
𝛽̂ (𝜆) =

𝑎𝑟𝑔𝑚𝑖𝑛
𝛽

(𝑛−1 ∑𝑛𝑖=1 𝜌𝛽 (𝑋𝑖 , 𝑌𝑖 ) + 𝜆 ‖𝛽‖1 )
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(4)

For a logistic regression where 𝑌𝑖 |𝑋𝑖 ~ 𝐵𝑖𝑛𝑜𝑚𝑖𝑎𝑙 (1, 𝜇𝑖 ), the negative log-likelihood equals
− ∑𝑛𝑖=1 log(𝑝𝛽 (𝑌𝑖 |𝑋𝑖 )) = ∑𝑛𝑖=1 {−𝑌𝑖 𝑓𝛽 (𝑋𝑖 ) + 𝑙𝑜𝑔 (1 + 𝑒𝑥𝑝 (𝑓𝛽 (𝑋𝑖 )))}

(5)

𝜇

Where 𝑓𝛽 (𝑋𝑖 ) = 𝑙𝑜𝑔𝑖𝑡(𝜇) = log (1−𝜇) = ∑𝑘𝑗=0 𝛽𝑗 𝑥𝑗 , and the corresponding loss function for (5)
is

𝑘

𝑘

𝜌𝛽 (𝑥, 𝑦) = −𝑦 (∑ 𝛽𝑗 𝑥𝑗 ) + 𝑙𝑜𝑔 (1 + 𝑒𝑥𝑝 (∑ 𝛽𝑗 𝑥𝑗 ))
𝑗=0

𝑗=0

Then, the lasso estimator for the logistic model is defined as that in (4).
Propensity Score (PS)

One of the challenges in the analysis of observational data such as EHR is the presence of
confounding bias. Because treatments were not given randomly, confounding can occur if the
underlying distribution of pretreatment covariates differ between the vasopressor treatment
groups. Hence, direct comparisons between the groups could result in a biased estimate of
treatment effects.24 However, propensity scoring (ps) methodology can be used to create
comparison groups which have similar values for observed confounders. In this way, the effect of
the type of treatment received could be isolated. PS was first introduced by Rosenbaum and Rubin
in 1983. It is defined as the conditional probability of assignment to a treatment given a vector of
observed covariates.24 The propensity score, 𝑒(𝑋𝑖 ) for the subject i, is given by
𝑒(𝑋𝑖 ) = 𝑃(𝑍 = 𝑘|𝑋𝑖 )
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where Z = k denotes kth treatment, and 𝑋𝑖 is the covariate matrix of that subject, and it is assumed
that X’s and Z’s are independent.25 PS modeling also requires positivity and exchangeability
assumptions. The positivity assumption states that all the subjects should have a non-zero
probability of receiving each treatment. A lack of overlap in the true distribution of pretreatment
characteristics between treatment groups implies a violation of this assumption. Exchangeability,
also called ignorable treatment assignment assumption, assumes that all true confounders are
measured and observed. This condition assumes that the set of observed pretreatment covariates is
sufficiently rich, and it includes all variables directly influencing both treatment and outcome.23
However, it is not possible to test this assumption. In this study, this assumption is violated,
because we could not include morbid and co-morbid factors due to the inherent nature of the data.
Causal-Estimands:
Average Treatment Effect (ATE) and Average Treatment Effect Among the Treated (ATT) are
two types of causal effect estimands that can be used to derive a summary measure of treatment
effect. The definition of ATE and ATT are slightly different, and the choice of this estimand
depends on the research question and the target population under treatment. ATE is a better
estimand if every member in the study population has equal opportunity to receive treatment.
However, ATT is the choice of estimand if the research question of interest is to study the
effectiveness of one treatment and if it were replacing an alternate form of treatment. Clearly, in
our analysis, ATE was the choice of estimand since it is plausible that every SAH patient had an
equal chance of receiving one of the three vasopressors, and the research question focuses on the
relative effect of three vasopressors on the outcome, mortality. Moreover, in a binary treatment
setting, ATE of a treatment (T) relative to a control (C) is the difference in the mean outcome, had
the study population was administrated T versus C. Likewise, in a setting with 3 treatments, there
14

exist three pairwise ATEs, and they can be interpreted as the difference in mean outcomes had the
study population was administrated one treatment k vs. a different treatment 𝑘̀. ATE can be
calculated as below26
𝐴𝑇𝐸𝑘,𝑘̀ = 𝐸 (𝑌(𝑘) − 𝑌(𝑘̀)) = 𝐸(𝑌(𝑘)) − 𝐸(𝑌(𝑘̀))
After defining the casual estimands appropriate for the research question, we can adjust for the
estimated propensity scores in one of the four ways: matching, stratifying, weighting and covariate
adjustment. In our analysis, we applied weighting via Inverse Probability Treatment Weights
(IPTW) of subjects to create a synthetic sample in which treatment assignment is independent of
the measured pretreatment covariates.27 The idea behind IPTW is to up-weight those who are
underrepresented and down-weight those who are overrepresented.23 The weight of a treated
subject is defined as the inverse of its propensity score (𝑤𝑖 = 1/𝑒(𝑋𝑖 ), and the weight of a control
subject is defined as the inverse of one minus its propensity score (𝑤𝑖 = 1/(1 − 𝑒(𝑋𝑖 ))).
PS estimation for multiple treatments:
Imbens34 extends Rosenbaum and Rubin’s work to multiple treatment cases by introducing the
concept of the generalized propensity score. The generalized propensity score r (t, X) is the
conditional probability of receiving treatment t given the pre-treatment variables X,
𝑟(𝑡, 𝑋) = 𝑃(𝑇𝑖 = 𝑡| 𝑋𝑖 ) = 𝐸{𝐼(𝑡)|𝑋 = 𝑋}
where T denotes the treatment received and takes on a value in a set T, and I(t) is the indicator of
receiving treatment t. Unbiased estimation of average treatment effects conditioning on the
generalized propensity score requires the assumption of weak ignorability. Weak ignorability is
defined as pairwise independence of the treatment assignment and potential outcomes.35 If weak
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ignorability holds, the inverse of the generalized propensity scores at each treatment level can be
used as weights to estimate the mean potential outcome, 𝜇̂𝑡 for each treatment level as shown
below
∑𝑛𝑖=1 𝑇𝑖 [𝑡]𝑌𝑖 𝑤𝑖 [𝑡]
𝜇̂𝑡 =
∑𝑛𝑖=1 𝑇𝑖 [𝑡]𝑤𝑖 [𝑡]
Where 𝑤𝑖 = 1/𝑃(𝑇𝑖 = 𝑡| 𝑋𝑖 )
Using GBM to obtain PS:

PS for multiple treatments can be estimated using multinomial regression or machine learning
methods. Considering the high dimensional nature of the SAH data, we used a machine learning
approach based on trees called the generalized boosted model (GBM). GBM can typically obtain
robust propensity score weights with better balance properties than the multinomial logistic
method.23 GBM estimation involves an iterative process with multiple regression trees to capture
complex and nonlinear relationships between treatment assignment and the pretreatment
covariates without over-fitting the data.23 GBM is fit to separate pairs of treatments which consider
one treatment as a holdout and estimates 𝑃(𝐼𝑖 (𝑡)|𝑋), where 𝐼𝑖 (𝑡) = {1 if 𝑇𝑖 = 𝑡, 0 otherwise}
using the estimated odds ratios of the probability assigned to each treatment versus the probability
assigned to the holdout treatment. Depending on the choice of holdout treatment, the estimated
probabilities might differ since this method relies on the binary estimation of the subsamples of
the population. The estimated propensity scores from each of the GBM fits is used to compute the
weights. McCaffrey states that the general intuition behind this approach is that, for any given
treatment, 𝑇𝑖 = 𝑡, estimating weights for a treatment group only requires knowing the probability
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that each case assigned to this group received that assignment rather than one to any other
treatment23.

We also used Toolkit for Weighting and Analysis of Nonequivalent Groups (twang 1.3)
packages in R for evaluation of propensity scores and associated weights. The multinomial
propensity scores (mnps) function in this package can handle more than two treatment conditions,
and it relies on GBM to generate numerous regression trees for estimating the propensity score
model, which could lead to the best balance between the treated and reference groups.23 In mnps,
the GBM is fitted to separate pairs of treatment, not to a multinomial model such as that in a
multinomial logistic regression model. Then, the estimated propensity scores from each of the
GBM fits are used to compute the weights. GBM uses stopping rules to select optimal iterations
to yield the best balance. These are based on summary statistics (mean, max) of the absolute
standardized mean difference (es) or the Kolmogorov Smirnov (ks) statistic. For covariate k (k =
1, … K) and treatment t (t = 1, … M), the population standardized mean difference, 𝑃𝑆𝐵𝑡𝑘 is given
by23
𝑃𝑆𝐵𝑡𝑘 =

̅̅̅̅
̅̅̅̅̅
|𝑋
𝑘𝑡 − 𝑋𝑘𝑝 |
⁄
𝜎̂
𝑘𝑝

Where ̅̅̅̅
𝑋𝑘𝑡 is the propensity score weighted mean of the covariate, ̅̅̅̅̅
𝑋𝑘𝑝 and 𝜎̂
𝑘𝑝 the unweighted
mean and standard deviation of the covariate for the pooled sample across all treatments. This
statistic measures the similarity of each treatment group to the population in terms of covariate
means both before and after weighting. Population KS (PKS) statistic for assessing balance with
multiple treatments is given by23
𝑃𝐾𝑆𝑡𝑘 =

𝑠𝑢𝑝
|𝐸𝐷𝐹𝑡𝑘 (𝑥) − 𝐸𝐷𝐹𝑝𝑘 (𝑥)|
𝑥
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Where 𝐸𝐷𝐹𝑡𝑘 (𝑥) = ∑𝑛𝑖=1 𝐼(𝑋𝑖𝑘 ≤ 𝑥)/𝑛 is the unweighted empirical distribution function for the
pooled sample across all treatments.

Assessing Covariate Balance:
After calculating IPTW, it is important to assess the balance. Treatment groups are considered
balanced if the absolute standardized mean differences are less than about 0.2. The “plot ()”
function was used to assess the balance graphically.

GLM approach for subgroup analysis

The first step in the GLM approach for subgroup analysis was using a lasso to identify the
covariates that were associated with treatment response. Glmnet package was used to implement
logistic regression modeling with the lasso penalty. The binary outcome variable, mortality, was
coded as 1 (death at hospital discharge or discharge to hospice), and 0 (survived), and the treatment
is coded as 1 (=Dopamine), 2 (=Phenylephrine), 3(=Norepinephrine). The covariates include
demographic factors (age, race, gender and marital status) and pretreatment medications. The base
model obtained after lasso penalized feature selection will be of the form below
𝜇
)
1−𝜇
= 𝛽0 + 𝛽1 𝐷𝑜𝑝𝑎𝑚𝑖𝑛𝑒 + 𝛽2 𝑁𝑜𝑟𝑒𝑝𝑖𝑛𝑒𝑝ℎ𝑟𝑖𝑛𝑒 + 𝛽3 𝑋𝑐1 + … . . +𝛽𝑘 𝑋𝑐𝑘

Pr(𝑌 = 1|𝑋) = log (

where 𝑋𝑐1 … . 𝑋𝑐𝑘 represent selected covariates using lasso penalized feature selection.
In order to identify the differential effect of treatment among the selected covariates, the treatmentcovariates interaction effect for each covariate is included in the base model. For selected covariate
𝑋𝑐1 , the interaction model will of the form below
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Pr(𝑌 = 1|𝑋) = 𝛽0 + 𝛽1 𝐷𝑜𝑝𝑎𝑚𝑖𝑛𝑒 + 𝛽2 𝑁𝑜𝑟𝑒𝑝𝑖𝑛𝑒𝑝ℎ𝑟𝑖𝑛𝑒 + 𝛽3 𝑋𝑐1 + … . . +𝛽𝑘 𝑋𝑐𝑘
+ 𝛽𝑘+1 𝐷𝑜𝑝𝑎𝑚𝑖𝑛𝑒 × 𝑋𝑐1 + 𝛽𝐾+2 𝑁𝑜𝑟𝑒𝑝𝑖𝑛𝑒𝑝ℎ𝑟𝑖𝑛𝑒 × 𝑋𝑐1
Similarly, the treatment-covariates interaction effect was studied for every selected covariate. The
base model and interaction model were then compared using a likelihood ratio test. To correct for
multiple comparisons, we used the false discovery rate (FDR) approach.
Machine learning approach for subgroup analysis using MOB
Model-based Recursive Partitioning (MOB) is a tree-based recursive partitioning method
proposed by Zeileis et al.28 MOB combines both regression modeling and tree structure for
automated detection of the patient subgroup. This involves fitting an M-type parametric model at
terminal nodes of the tree structure. Like other methods based on classification and regression trees
(CART), MOB also uses recursive partitioning methods to create a decision tree. CART finds
optimal cuts or dichotomizations in variables, and then finds the best cut among the groups created
by previous cuts, hence identifying higher-order covariate interactions.29 MOB is more suitable
for subgroup analysis since it restricts interactions to treatment × covariate interactions.
MOB algorithm works by fitting a logistic regression model with mortality as the response
variable and vasopressor treatment as a control variable, and it fits on all observations using
maximum likelihood estimation. For n observation of 𝑌𝑖 , (𝑖 = 1, … 𝑛) the parametric model can
be fitted, and its parameter estimate 𝜃̂ can be calculated by minimizing objective function
𝛹(𝑌, 𝜃) such that
𝑛

𝜃̂ =

𝑎𝑟𝑔𝑚𝑖𝑛
𝜃

∑ 𝛹(𝑌𝑖 , 𝜃𝑖 )
𝑖=1
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Further, the algorithm tries to detect pretreatment covariate effects by testing parameter
instability. The parameter instability was assessed with respect to each pretreatment covariate
while controlling for the vasopressor treatment. The parameter instability was assessed to
determine which variable should be used for partitioning. This is assessed using a score function,
̂ = 𝛹(𝑌𝑖 , 𝜃̂), for systematic deviations from their mean 0 over possible covariates. These
𝛹
deviations are captured by the empirical fluctuation of the process21
⌊𝑛𝑡⌋

̂−1/2

𝑊𝑗 (𝑡) = 𝐽

𝑛

−1/2

̂ 𝜎(𝑋𝑖𝑗 )
∑𝛹

(0 ≤ 𝑡 ≤ 1)

𝑖=1

where 𝜎(𝑥𝑖𝑗 ) is the ordering permutation which gives the antirank of the observation 𝑋𝑖𝑗 in the
vector of covariates 𝑋𝑗 , and 𝐽̂ is the covariance matrix 𝐶𝑜𝑣 (𝛹(𝑌𝑖 , 𝜃̂)). This framework of testing
parameter stability is established by Zeileis et al.30
If the overall null hypothesis of no instability (for any of the parameters) is not rejected,
we assume there are no (further) subgroups.29 However, if the null hypothesis is rejected, this
implies there is instability. Then, the variable with the smallest p-value will have the highest
parameter instability. Further, the sample is partitioned into subgroups with respect to this split
variable using a binary split. When more than two splits are possible, the split which minimizes
the objective function of the model in the two resulting subgroups will be chosen.29 Then the new
model will be fitted in each subgroup, and the parameters of each model will be tested again for
instability. This process is repeated until no more parameter instability is observed, or minimum
sample is reached. MOB uses Bonferroni correction to adjust for multiple testing. We used
‘partykit’ package and glmtree function in R to implement model-based Recursive Partitioning.
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Sensitivity Analysis adjusting for heart rate and blood pressure
Since only 39% of the non-traumatic SAH patient’s heart rate and blood pressure values were
available, a separate analysis on subjects (n= 940) was conducted to adjust for these variables.

Results
Summary Statistics
The baseline characteristics of 2415 non-traumatic SAH patients are displayed in Table 1. Besides
demographic and vital sign factors, 750 pretreatment medication variables were also considered in
our analysis. Since the medical diagnoses such as heart disease and diabetes were unknown before
or after the vasopressor treatment, we assumed that the pretreatment medications would capture
the clinical subgroups. Except for gender, most of the baseline characteristics had a statistically
significant difference between the treatment groups.
Table 1: Baseline characteristics of non-traumatic SAH patients by vasopressor treatment group
Characteristic
N (%)
Age, years, mean (SD)
Male Sex, n (%)

Total
2415
56.5
(14.8)
879
(36.4)

Phenylephrine
1251 (51.8)
56.28
(14.34)
459
(36.6)

Dopamine
492 (20.3)
58.1
(15.4)
172
(34.9)

Norepinephrine
672 (27.8)
55.62
(15.16)
248
(36.9)

Race, n (%)
African American
White
Other

0.021
0.75
<0.001

549
(22.7)
1609
(66.6)
257
(10.6)

243
(19.4)
867
(69.3)
141
(11.2)

114
(23.1)
325
(66.0)
53
(10.7)

192
(28.5)
417
(62.0)
63
(9.4)

Marital Status, n (%)
Divorced

p-value
<0.001

0.004
258
(10.6)

133
(10.6)
21

46
(9.3)

79
(11.7)

Married
Single
Widowed
Unknown
Mortality, n (%)

1098
(45.4)
637
(26.4)
180
(7.4)
242
(10.0)
879
(36.4)

576
(46.0)
327
(26.1)
79
(6.3)
136
(10.8)
317
(25.3)

225
(45.7)
113
(22.9)
48
(9.7)
60
(12.2)
251
(51.0)

297
(44.2)
197
(29.3)
53
(7.8)
46
(6.8)
311
(46.2)

115.31
(31.74)
65.41
(17.31)
82.94
(23.65)

117.44
(29.99)
63.06
(17.7)
91.96
(24.63)

<0.001

Blood pressure (mmHg),
mean (SD)
Systolic*
Diastolic*
Heart Rate, mean* (SD)

122.6
(28.8)
65.6
(16.2)
84.14
(21.76)

126.34 (27.17)
66.87
(15.08)
80.44
(18.75)

<0.001
<0.001
<0.001

* calculated for subsample n=940

Multinomial lasso and GBM
The first objective in our analysis was to create covariate balanced data. For this purpose, we
conducted variable selection using L1-penalized generalized linear models prior to GBM. We used
the cv.glmnet function in R with 10-fold cross validation to estimate an optimal value of 𝜆. The
prediction error curve as a function of 𝜆 is shown in Figure 1. We chose the 𝜆 = 0 .012 that yielded
the lowest cross-validated prediction error. After the initial multinomial lasso variable selection
for the treatment model, 159 out of 750 medication covariates were selected along with paitents’
age, race and marital status. We included all these selected factors into GBM to generate a
propensity score model and the corresponding IPTWs. The ‘mnps’ function in the twang package
was used with parameter settings of “n.trees” = 6000, “estimand” = ATE and “stop.method”=
"es.mean", "ks.mean". Figure 2 shows the graphical assessment of balance achieved through
inverse probability treatment weighting. Figure 2a shows that maximum absolute standardized
mean difference (AMSD) decreases for all pretreatment covariates after weighting for both
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stopping rules. As a rule of thumb, AMSD less than 0.2 is required to achieve a good balance. In
our case, after weighting, AMSD less than 0.3 is achieved, which could be considered as a
moderate to good balance.26 The Figure 2b shows that pairwise minimum p-values increased after
propensity score weighting (hollow circle). The 45-degree line in this figure shows qline
corresponds to the quantiles in the uniform distribution. When the null hypothesis is true, the pvalues from the independent test should follow a uniform distribution.31 The large deviation of the
solid circle from this 45-degree line shows the lack of balance before weighting. After weighting,
the fact that the p-value has been brought closer to the 45-degree line confirms there was an
improvement in covariate balance between the treatment groups.
Figure 1: Plot of the misclassification error and the number of variables in the model as functions
of -log( λ) for the 10-fold cross-validation analyses. The lowest point in the curve indicates the
optimal lambda.
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Figure 2a: The maximum pairwise absolute standardized mean differences of the pretreatment
covariates before and after weighting based on es.mean and ks.mean stopping rule.

Figure 2b: QQ plot comparing the quantiles of the observed p-values to the quantiles of the
uniform distribution
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Subgroup Analysis: Binary lasso and Interaction studies
After constructing balanced data, we proceeded with subgroup analysis. At first, we conducted
variable selection using L1-penalized generalized linear models. However, here we were only
interested in finding covariates associated with mortality. So, we used cv.glmnet with 10-fold
crossvalidation and estimated an optimal value of λ. We observed that age, total fluids
administered, and vasopressor treatment were associated with mortality. Additionally, 58 out of
the 750 pretreatment medications were associated with mortality. Utilizing these significant
factors, the base model was constructed as below:
Pr(𝑀𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦 = 1|𝑋) = 𝛽0 + 𝛽1 𝐷𝑜𝑝𝑎𝑚𝑖𝑛𝑒 + 𝛽2 𝑁𝑜𝑟𝑒𝑝𝑖𝑛𝑒𝑝ℎ𝑟𝑖𝑛𝑒 + 𝛽3 𝑋𝑐1 + … . . +𝛽63 𝑋𝑐60
where 𝑋𝑐1 … . 𝑋𝑐60 represent selected covariates using lasso penalized feature selection. Further,
with respect to each selected 60 covariates, 60 interaction models were constructed as follows:
Interaction model 1:
Pr(𝑀𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦 = 1|𝑋)
= 𝛽0 + 𝛽1 𝐷𝑜𝑝𝑎𝑚𝑖𝑛𝑒 + 𝛽2 𝑁𝑜𝑟𝑒𝑝𝑖𝑛𝑒𝑝ℎ𝑟𝑖𝑛𝑒 + 𝛽3 𝑋𝑐1 + … . . +𝛽63 𝑋𝑐60
+ 𝛽64 𝐷𝑜𝑝𝑎𝑚𝑖𝑛𝑒 × 𝑋𝑐1 + 𝛽65 𝑁𝑜𝑟𝑒𝑝𝑖𝑛𝑒𝑝ℎ𝑟𝑖𝑛𝑒 × 𝑋𝑐1
Interaction model 60:
Pr(𝑀𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦 = 1|𝑋)
= 𝛽0 + 𝛽1 𝐷𝑜𝑝𝑎𝑚𝑖𝑛𝑒 + 𝛽2 𝑁𝑜𝑟𝑒𝑝𝑖𝑛𝑒𝑝ℎ𝑟𝑖𝑛𝑒 + 𝛽3 𝑋𝑐1 + … . . +𝛽63 𝑋𝑐60
+ 𝛽64 𝐷𝑜𝑝𝑎𝑚𝑖𝑛𝑒 × 𝑋𝑐60 + 𝛽65 𝑁𝑜𝑟𝑒𝑝𝑖𝑛𝑒𝑝ℎ𝑟𝑖𝑛𝑒 × 𝑋𝑐60
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We used svyglm function in R to incorporate with IPTW obtained from GBM. Further, a likelihood
ratio test was used to compare the base model with each interaction model. In order to account for
multiple comparisons, we used the FDR correction procedure. The results indicated that only
pretreatment medication of amitriptyline (Med_lable_34563) had significant vasopressormedication interaction. Table 2 shows the coefficient estimate and the p-value for the significant
interaction model.
Further, in order to understand the vasopressor effect in the presence and absence of amitriptyline,
we calculated various effects as shown in Table 3. Utilizing these effects, we calculated the odds
ratio and the corresponding confidence interval. For instance, the odds ratio comparing dopamine
to phenylephrine among those who had amitriptyline was calculated by subtracting effect (4) –
effect (2). Similarly, the odds ratio comparing norepinephrine to phenylephrine among those who
had amitriptyline was calculated by subtracting effect (6) – effect (2). Likewise, effect (3) –effect
(1) gave the odds ratio comparing dopamine to phenylephrine among those who did not have
amitriptyline. Besides, to find the odds ratio comparing norepinephrine to phenylephrine among
those who did not have amitriptyline, we subtracted the effect (1) from effect (5). The results are
shown as a forest plot in Figure 3.
Table 2: Coefficient estimate (p-value) for outcome model fitted with IPTW, vasopressor
treatment indicator (with ref: phenylephrine) and its interaction term with amitriptyline after
adjusting for pretreatment variables.
Effects
Intercept
Dopamine
Norepinephrine
Amitriptyline
Dopamine× Amitriptyline
Norepinephrine× Amitriptyline

Model with Vasopressor- amitriptyline interaction
0.47 (<0.001)
0.129 (<0.001)
0.125 (<0.001)
0.269 (<0.001)
-0.49(<0.001)
Not estimated due to small sample sizes
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Table 3: Calculation of various treatment effect based on the interaction model.
Logit(P(Y=1) where
Pretreatment Medication (Prt Med.)
the coefficient for
Effect Vasopressor
(Each variable from 𝑋𝑐1 , … , 𝑋𝐶60 with
Prt Med is
corresponding coefficients 𝛽3 , … , 𝛽63)
represented as 𝛽𝑖
𝛽0
1
Phenylephrine (Ph)
Not given
𝛽0 + 𝛽𝑖
2
Phenylephrine (Ph)
Given
𝛽0 + 𝛽1
3
Dopamine (Do)
Not given
𝛽0 + 𝛽1 + 𝛽𝑖 + 𝛽64
4
Dopamine (Do)
Given
𝛽0 + 𝛽2
5
Norepinephrine (Nor) Not given
𝛽0 + 𝛽2 + 𝛽𝑖 + 𝛽65
6
Norepinephrine (Nor) Given
The results showed that dopamine and norepinephrine had higher mortality compared to
phenylephrine based on the base model without interaction. The odds ratio of mortality of
dopamine compared to that of phenylephrine among those who had amitriptyline was 0.69, and
95% CI was (0.55,0.88); however, the odds ratio among those who did not have amitriptyline was
1.13, and 95% CI was (1.08, 1.19). We did not observe a statistically significant interaction effect
between amitriptyline and norepinephrine. When we examined the number of subjects who had
amitriptyline stratified by the type of vasopressor and mortality (Table 5), the results showed that
amitriptyline was never administered to the subjects who had norepinephrine.
Table 4: The OR and 95% confidence interval for the association of treatment with mortality
using IPTW after adjusting for pretreatment variables
Effects
For the base model without interaction
Dopamine
Norepinephrine
Phenylephrine
Amitriptyline given
Dopamine
Norepinephrine
Phenylephrine
Amitriptyline not given
Dopamine

OR

(95% Confidence interval)

1.13
1.13
Ref

(1.07, 1.19)
(1.08, 1.18)
Ref

0.69
(0.55, 0.88)
Not estimated due to small sample sizes
Ref
Ref
1.13
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(1.08, 1.19)

Norepinephrine
Phenylephrine

1.13
Ref

(1.08, 1.18)
Ref

Figure 3: Forest plot showing odds ratios and confidence interval comparing dopamine and
norepinephrine to phenylephrine, in presence and absence of amitriptyline.

* Odds ratio for the base model without interaction. ~ Odds ratio for amitriptyline interaction model. All odds ratio is adjusted for
significant pretreatment covariates from the lasso model.

Table 5: The number of subjects who had amitriptyline stratified by type of vasopressor and
mortality
Mortality

Survived

Dead

amitriptyline
Vasopressor

Not given

Given

phenylephrine

926

8

dopamine

240

1

norepinephrine

361

0

phenylephrine

309

8

dopamine

251

0

norepinephrine

311

0

Subsample analysis
As described above, subgroup analysis was repeated on complete cases (N=940) for which heart
rate and blood pressure values were available. After conducting the propensity score modeling,
covariate balance was assessed, and a balance as in shown Figure 2a and 2b was observed. Further,
the lasso and interaction effect analysis were conducted. In subsample analysis, none of the
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medications was observed to have a significant interaction effect with the vasopressor treatment
group.

Model-based Recursive Partitioning (MOB)
We used MOB, a machine learning approach to capture the differential vasopressor treatment
effect across the subgroups. In order to implement MOB, we utilized glmtree function in R. To
account for covariate imbalance within the data, we used IPTW calculated through GBM. As
shown in Figure 4, for sample size N=2,415, ondansetron, fentanyl, mannitol, lidocaine, and age
were the partitioning variables selected for the tree. The terminal node in Figure 4 has a boxplot
comparing mortality (as y) across the vasopressor treatment group (as x) for that subgroup. The
fitted lines are the mean predicted probabilities in each group. Since automatically generated
boxplot is unclear, Table 6 is included to show the distribution of the number of subjects for each
subgroup stratified by treatment and mortality.
The results showed that among those who had ondansetron, the treatment effect on
mortality followed a similar pattern across the age subgroups: phenylephrine was associated with
lower odds of mortality, and norepinephrine was associated with higher odds of mortality.
Moreover, it can be observed that across all terminal nodes, the rate of mortality was lower among
those who had ondansetron compared those who did not have ondansetron. Between all nodes,
phenylephrine was consistently observed to be associated with lower mortality, and dopamine
seemed to be associated with higher odds of mortality among those who did not have ondansetron.
In Figure 5, an equivalent observation was found for a subsample (n=940). Based on the subsample
data consisting of complete cases with heart rate and blood pressure values, the significant
subgroup was identified only with the pretreatment medication of ondansetron. The mortality is
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much lower among those who had ondansetron where phenylephrine was associated with lower
odds of mortality. Among those who had ondansetron, norepinephrine was associated with higher
odds of mortality. However, among those who did not have ondansetron, dopamine was associated
with higher odds of mortality.
Figure 4: Logistic-regression-based tree for the n= 2,415. The plots in the leaves show boxplot
for mortality by vasopressor treatment group

Table 6: Number of subjects for each subgroup stratified by treatment and mortality

Node

Mortality

Phenylephrine

dopamine

norepinephrine

N

4

0
1
0
1
0
1

155
97
23
50
112
72

61
141
12
38
21
31

71
141
5
28
61
51

666

5
7

30

156
348

8

0
1
0
1
0
1

10
11

125
36
423
36
96
26

30
12
90
19
27
10

50
12
152
56
22
23

265
776
204

Figure 5: Logistic-regression-based tree for the n = 940. The plots in the leaves show boxplots
for mortality by vasopressor treatment group

Discussion
A previous study on Cerner-based SAH patient records showed that among the three
vasopressors, dopamine, phenylephrine, and norepinephrine, phenylephrine administration has
been associated with a lower rate in mortality. On this account, we were interested in investigating
if this overall effect was generalizable to all SAH patients. In order to examine this, a subgroup
analysis was conducted to study the differential vasopressor treatment effect among the SAH
patients. We performed subgroup analysis through a generalized linear model and a machine
learning tree-based approach.
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Pretreatment administration of ondansetron was a significant factor since it had a
differential treatment effect based on the tree-based method. Ondansetron is selective serotonin 5HT3 (5- hydroxytryptophan 3) antagonist that is used to prevent nausea and vomiting associated
with several conditions including anesthesia and surgery.32 Based on the mob results (Figures 4
and 5), among those who had ondansetron, the predicted probability of mortality is lower
compared to those who did not have ondansetron after controlling for the vasopressor treatment
group. Besides among those who had ondansetron, phenylephrine was associated with the lowest
mortality, and norepinephrine was associated with the highest mortality. Metanalysis on the effects
of ondansetron on spinal anesthesia-induced hypotension showed that though ondansetron is
commonly used as an antiemetic, it can also reduce the incidence of hypotension and bradycardia
as well as the need of vasopressor requirement.33 Our observation based on mob also aligns with
this result: with the administration of ondansetron, norepinephrine and dopamine can be avoided
since ondansetron along with phenylephrine has a better survival rate. However, whether
vasopressor is required along with ondansetron needs to be further examined.
Based on mob analysis, we also observed that among those who had ondansetron, there
were two subgroups by age. The SAH patients aged 66 or older had a higher probability of
mortality compared to the younger patients. However, both age subgroups had lower mortality
compared to those who did not have ondansetron except in one subgroup. This subgroup included
those who did not have ondansetron but had fentanyl and lidocaine. Fentanyl is a synthetic opioid
that is 80-100 times stronger than morphine and lidocaine, and it is an anesthetic and
antiarrhythmic drug. Though this subgroup falls under those who did not have ondansetron, they
had mortality in a similar range to those who had ondansetron with respect to all three
vasopressors.
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In contrast, amitriptyline was the only medication that was observed to be significant based
on a generalized linear model approach. The odds ratio of mortality of dopamine compared to that
of phenylephrine among those who had amitriptyline was lower (OR= 0.69 and 95% CI =
0.55,0.88) compared to those who did not have amitriptyline (OR= 1.13 and 95% CI = 1.08, 1.19).
However, this medication was administrated to only 17 out of the 2,415 subjects. Hence, the
inference based on this result could be spurious. A literature search showed a tricyclic
antidepressant agent, such as amitriptyline was often administrated to SAH survivors who had a
sign of depression.36 This may indicate amitriptyline is not a pretreatment medication; however,
for amitriptyline toxicity, vasopressor could be used to manage hypotension, even though are not
first-line therapy.
On other hand, when fitting a generalized linear model on the subsample for which heart
rate and blood pressure values are available, we did not observe any significant interactions. A
major difference between the generalized linear model approach and mob-based subgroup analysis
was that, in the mob, the multiple-level interactions with treatment were studied. However, in our
generalized model approach, we only looked at the first-order interaction since interpreting higherorder interactions are difficult.
This study has several limitations. First, the EHR data are retrospective, and the vasopressor
treatments were not administered randomly. However, it would be very hard and expensive to
address this limitation in clinical trial settings because SAH is rare. So, this database is an
important source to investigate these questions. Second, all the important factors that led to the
choice of the right vasopressor may not be captured in the database; therefore, there is a high
likelihood of having not included unmeasured confounding effects such as information on clinical
severity level and baseline diagnostic and labs. If there are unmeasured confounding effects, the
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exchangeability assumption for propensity modeling will be violated. Consequently, there could
be a potential for selection bias. Of course, the medications may have captured some of these
variables, and we observed moderate to good covariate balance after the inverse probability
weighting. However, including any unmeasured confounders in future studies would be helpful to
understand differential treatment with respect to morbidities and comorbidities. Third, because
each hospital could choose what data elements to upload, the database has a high percentage of
missing blood pressure values. In sensitivity analyses; however, we did not detect important
differences between those that had and those who did not have blood pressure values; and when
repeating the analysis in the subgroup that did have blood pressure, the results were mainly
consistent. Another limitation is that, in our analysis primary exposure of interest is the first
vasopressor administered to eligible patients, however about 6% patients were given all three
vasopressors, and about 30% patients received a second vasopressor after the initial vasopressor.
Since we were interested in association of mortality with first choice vasopressor, our analysis did
not consider the second and third vasopressor administrated. But it is important acknowledge the
fact that second and third medication also influence on vasopressor treatment effect.

Conclusion
In this thesis, we conducted an exploratory analysis to identify subgroups within the SAH patient
data based on their vasopressor treatment effect on mortality. The machine learning approach
(mob) and statistical approach (GLM) generated different results. This difference, however, could
be the result of the inherent differences of the two methodologies. In GLM, we only looked at the
first order interaction, and we did not observe any significant interaction effect. Whereas in mob,
higher-order interactions were studied, and significant interaction effects were observed with
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second-degree and third-degree interactions. The mob result suggests that among those who had
ondansetron, norepinephrine was associated with the highest mortality rate, and among those who
did not have ondansetron, dopamine was associated with the highest mortality. For the subgroup
who did not have ondansetron, but fentanyl and lidocaine, there is no significant difference in the
mortality rate between the three vasopressors. Though literature suggests ondansetron can reduce
the incidence of hypotension, ondansetron is not widely used in medical practice for this purpose,
and hence the clinical significance of the interaction effect of an antiemetic agent such as
ondansetron and vasopressor is not clearly understood. It could be considered that the observed
significant interaction effect was a marker of certain patients’ conditions. But in order to rule out
this further analyses considering the pretreatment diagnosis and relevant lab factors are required.
However, those who has ondansetron had better survival compared to those who did not have
ondansetron with respect to all the three vasopressor. Besides, in general, among three
vasopressors, phenylephrine was associated with lower mortality compared to dopamine and
norepinephrine.
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Appendices
Appendix I
Summary of variables

Variables

Type

Vasopressor treatment

Categorical 2

Medication generic names prior to
vasopressor treatment

Binary

750

Age

Numeric

1

Race

Categorical 2

Gender

Binary

Marital status

Categorical 3

Vital signs (HR, SBP, DBP)

Numeric

3

Total fluids administered

Numeric

1
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Number of variables/dummy
variables

1

